Quincy Bioscience Raises Funding from DaneVest Tech Fund I

Quincy Bioscience, a Madison, Wisconsin-based biotechnology company focused on the discovery, development and commercialization of novel compounds to fight the aging process, has recently received a capital infusion from DaneVest Tech Fund I.

The funding – whose amount remained undisclosed, will be used to help support national sales of the company’s Prevagen® – Brain Cell Protection, a brain health product that improves cognitive performance in those with memory concerns.

Launched in 2007 Prevagen contains the active ingredient apoaequorin, a calcium-binding protein which helps to buffer excess calcium from damaging neurons in aging.